Industries > Pharma > Autoimmune Disease Therapeutics Market Report to 2031
Autoimmune Disease Therapeutics Market Report to 2031
By Indication (Rheumatic Disease, Multiple Sclerosis, Diabetes, Inflammatory Bowel Disease, Other), By Drug Class (Immunosuppressant drugs, Nonsteroidal anti-inflammatory drugs (NSAIDs), Biologics, Corticosteroids, Others), By Distribution Channel (Hospital Pharmacy, Online Pharmacies, Other), By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)
Autoimmune Disease Therapeutics Market– our new study reveals trends, R&D progress, and predicted revenues
Where is the Autoimmune Disease Therapeutics market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our Autoimmune Disease Therapeutics report provides tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Autoimmune Disease Therapeutics Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), product profiles and commercial developments.
Autoimmune Disease Therapeutics Market by Indication
• Rheumatic Disease
• Multiple Sclerosis
• Diabetes
• Inflammatory Bowel Disease
• Other
Autoimmune Disease Therapeutics Market by Drug Class
• Immunosuppressant drugs
• Nonsteroidal anti-inflammatory drugs (NSAIDs)
• Biologics
• Corticosteroids
• Others
Autoimmune Disease Therapeutics Market by Distribution Channel
• Hospital Pharmacy
• Online Pharmacies
• Other
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Japan
o Rest of Asia Pacific
• Latin America
o Rest of Latin America
• Middle East and Africa
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Autoimmune Disease Therapeutics Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Autoimmune Disease Therapeutics Market with forecasts for by Indication, by drug class, and Distribution channel each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments
Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Autoimmune Disease Therapeutics Market report helps you
In summary, our 320+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Autoimmune Disease Therapeutics Market, with forecasts for by indication, by drug class, and distribution channel each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 20 key national markets – See forecasts for the Autoimmune Disease Therapeutics market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, Rest of Asia Pacific, Latin America and Middle East and Africa among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for Autoimmune Disease Therapeutics of the major companies involved in the Autoimmune Disease Therapeutics Market. Some of the company’s profiled in this report include-
• ABBOTT Laboratories
• Hoffmann-La Roche AG
• Johnson and Johnson
• Bio-Rad Laboratories, Inc.
• Pfizer, Inc
• Bristol-Myers Squibb
• GlaxoSmithKline PLC
• Biogen Inc
• Bayer AG
• Merck & Co., Inc.
• AbbVie, Inc.
• Sanofi
• Chugai Pharmaceutical Co. Ltd.
• Amgen, Inc.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
With Information found nowhere else
our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.
Visiongain’s study is for everybody needing commercial analyses for the global Autoimmune Disease Therapeutics Market and leading companies. You will find data, trends, and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Autoimmune Disease Therapeutics Market Report to 2031: By Indication (Rheumatic Disease, Multiple Sclerosis, Diabetes, Inflammatory Bowel Disease, Other) By Drug Class (Immunosuppressant drugs, Nonsteroidal anti-inflammatory drugs (NSAIDs), Biologics, Corticosteroids, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacies, Other). Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Autoimmune Disease Therapeutics Market
2.1. Autoimmune Disease Therapeutics Market Definition
2.2. By Indication Submarkets Definitions
2.3. By Drug Class Submarkets Definitions
2.4. By Distribution Channel Submarkets Definitions
3. Autoimmune Disease Therapeutics Market Overview
3.1. Global Autoimmune Disease Therapeutics Market Size and Forecast by Region
3.2. Global Autoimmune Disease Therapeutics Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Surge in adoption of autoimmune disease therapeutics.
3.3.1.2. Rising prevalence of autoimmune disease.
3.3.1.3. Orphan Drug Act boosts market growth.
3.3.1.4. Increasing availability of advanced therapeutics.
3.3.2. Market Restraints/Challenges
3.3.2.1. Higher cost associated with advanced therapeutics for autoimmune disease
3.3.2.2. Lack of investments in the developing economies.
3.3.3. Opportunities
3.3.3.1. Increasing presence of pipeline drug
3.3.3.2. Significant advancement in therapeutics.
3.3.4. Porter’s Five Forces Analysis
3.3.4.1. Competitive Rivalry
3.3.4.2. Supplier Power
3.3.4.3. Buyer Power
3.3.4.4. Threat of Substitution
3.3.4.5. Threat of New Entry
4. Global Autoimmune Disease Therapeutics Market Analysis and Forecast 2021-2031, By Indication (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Rheumatic Disease
4.1.2. It is long-term autoimmune disorder, which primarily affects joints.
4.1.3. Multiple Sclerosis
4.1.4. The multiple sclerosis is potentially disabling disease of the brain and spinal cord.
4.1.5. Diabetes
4.1.6. Type 1 diabetes is autoimmune disease; the children with type 1 diabetes are at risk of other autoimmune disorder.
4.1.7. Inflammatory Bowel Disease
4.1.8. Crohn's disease is type of inflammatory bowel disease, characterized by inflammation of the lining of digestive tract.
4.1.9. Other
5. Global Autoimmune Disease Therapeutics Market Analysis and Forecast, 2021-2031 By Drug Class (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Immunosuppressant drugs
5.1.2. The drug is used to treat certain autoimmune diseases, such as lupus and rheumatoid arthritis.
5.1.3. Nonsteroidal anti-inflammatory drugs (NSAIDs)
5.1.4. The Nonsteroidal anti-inflammatory drugs such as aspirin and ibuprofen, enables to reduce pain and inflammation.
5.1.5. Biologics
5.1.6. Biologics categorized as Tumor necrosis factor (TNF) inhibitors; Interleukin (IL) inhibitors; B-cells inhibitors; and T-cells inhibitors to treat biologic autoimmune disease.
5.1.7. Corticosteroids
5.1.8. Corticosteroids are a class of drug, enables to reduce inflammation in the body.
5.1.9. Others
6. Global Autoimmune Disease Therapeutics Market Analysis and Forecast, 2021-2031 Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Hospital Pharmacy
6.1.2. Extensively increasing demand in hospitals.
6.1.3. Online Pharmacies
6.1.4. Increasing demand for online pharmacies due to pandemic impact.
6.1.5. Other
7. North America Autoimmune Disease Therapeutics Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Autoimmune Disease Therapeutics Market Size and Forecast By Indication
7.3. North America Autoimmune Disease Therapeutics Market Size and Forecast By Drug Class
7.4. North America Autoimmune Disease Therapeutics Market Size and Forecast By Distribution Channel
7.5. U.S. Autoimmune Disease Therapeutics Market
7.5.1. Increasing FDA approved orphan drug designation to treat autoimmune diseases.
7.6. Canada Autoimmune Disease Therapeutics Market
7.6.1. Approval of biologics therapy in the region.
8. Europe Autoimmune Disease Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Autoimmune Disease Therapeutics Market Size and Forecast By Indication
8.3. Europe Autoimmune Disease Therapeutics Market Size and Forecast By Drug Class
8.4. Europe Autoimmune Disease Therapeutics Market Size and Forecast By Distribution Channel
8.5. UK Autoimmune Disease Therapeutics Market
8.5.1. Increasing incentives to encourage the development of medicinal products for the treatment of rare diseases.
8.6. Germany Autoimmune Disease Therapeutics Market
8.6.1. Approval of MabThera to treat four autoimmune diseases in the region.
8.7. France Autoimmune Disease Therapeutics Market
8.7.1. Increasing healthcare awareness and emerging need for autoimmune disease therapeutics in the region.
8.8. Rest of Europe Autoimmune Disease Therapeutics Market
9. Asia Pacific Autoimmune Disease Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Autoimmune Disease Therapeutics Market Size and Forecast By Indication
9.3. Asia Pacific Autoimmune Disease Therapeutics Market Size and Forecast By Technology
9.4. Asia Pacific Autoimmune Disease Therapeutics Market Size and Forecast By Distribution Channel
9.5. China Autoimmune Disease Therapeutics Market
9.5.1. Rising prevalence of systemic sclerosis (SSc) in the region.
9.6. India Autoimmune Disease Therapeutics Market
9.6.1. Increasing prevalence of Grave's and Hashimoto's, inflammatory bowel diseases in the region.
9.7. Japan Autoimmune Disease Therapeutics Market
9.7.1. Increasing incidences of autoimmune disorder.
9.8. Rest of Asia Pacific Autoimmune Disease Therapeutics Market
10. Latin America Autoimmune Disease Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Autoimmune Disease Therapeutics Market Size and Forecast By Indication
10.3. Latin America Autoimmune Disease Therapeutics Market Size and Forecast By Drug Class
10.4. Latin America Autoimmune Disease Therapeutics Market Size and Forecast By Distribution Channel
10.4.1. Brazil Autoimmune Disease Therapeutics Market
10.4.1.1. Increasing risk of autoimmune disorder & lack of specific polices.
10.4.2. Mexico Autoimmune Disease Therapeutics Market
10.4.2.1. Prevalence of Arthritis in the region.
10.4.3. Rest of Latin America Autoimmune Disease Therapeutics Market
11. MEA Autoimmune Disease Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Autoimmune Disease Therapeutics Market Size and Forecast By Indication
11.3. MEA Autoimmune Disease Therapeutics Market Size and Forecast By Drug Class
11.4. MEA Autoimmune Disease Therapeutics Market Size and Forecast By Distribution Channel
11.5. South Africa Autoimmune Disease Therapeutics Market
11.5.1.1. Lack of awareness among population.
11.6. Rest of MEA Autoimmune Disease Therapeutics Market
12. Companies in the Autoimmune Disease Therapeutics Market
12.1. 1. Abbott Laboratories
12.1.1. Company Snapshot
12.1.2. Company Overview
12.1.3. Financial Performance (2015-2020)
12.1.3.1. Net Revenue
12.1.4. Product Offerings
12.1.5. Recent Initiatives (2017-2020)
12.2. Hoffmann-La Roche AG
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2020)
12.2.3.1. Net Revenue
12.2.3.2. Geographical Revenue, 2020
12.2.4. Product Offerings
12.2.5. Recent Initiatives (2017-2020)
12.3. Johnson and Johnson
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2020)
12.3.3.1. Net Revenue
12.3.3.2. Gross Profit
12.3.3.3. Geographical Revenue, 2020
12.3.4. Product Offerings
12.3.5. Recent Initiatives (2017-2020)
12.4. Bio-Rad Laboratories, Inc.
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2020)
12.4.3.1. Net Revenue
12.4.3.2. Gross Profit
12.4.3.3. Geographical Revenue, 2020
12.4.4. Product Offerings
12.4.5. Recent Initiatives (2017-2020)
12.5. Pfizer, Inc
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2020)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2020
12.5.4. Product Offerings
12.5.5. Recent Initiatives (2017-2020)
12.6. Bristol-Myers Squibb
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2020)
12.6.3.1. Net Revenue
12.6.3.2. Geographical Revenue, 2020
12.6.4. Product Offerings
12.6.5. Recent Initiatives (2017-2020)
12.7. GlaxoSmithKline PLC
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2020)
12.7.3.1. Net Revenue
12.7.3.2. Geographical Revenue, 2020
12.7.4. Product Offerings
12.7.5. Recent Initiatives (2017-2020)
12.8. Biogen Inc
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2020)
12.8.3.1. Net Revenue
12.8.3.2. Geographical Revenue, 2020
12.8.4. Product Offerings
12.8.5. Recent Initiatives (2017-2020)
12.9. Bayer AG
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2020)
12.9.3.1. Net Revenue
12.9.3.2. Geographical Revenue, 2020
12.9.4. Product Offerings
12.9.5. Recent Initiatives (2017-2020)
12.10. Merck & Co., Inc.
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2020)
12.10.3.1. Net Revenue
12.10.3.2. Geographical Revenue, 2020
12.10.4. Product Offerings
12.10.5. Recent Initiatives (2017-2020)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Autoimmune Disease Therapeutics Market Drivers & Restraints 2021
Table 7. Autoimmune Disease Therapeutics Submarket Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Autoimmune Disease Therapeutics Submarket Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Autoimmune Disease Therapeutics Submarket Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Autoimmune Disease Therapeutics Submarket Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Autoimmune Disease Therapeutics Submarket Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Rheumatic Disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Rheumatic Disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Rheumatic Disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Rheumatic Disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Rheumatic Disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Multiple Sclerosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Multiple Sclerosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Multiple Sclerosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Multiple Sclerosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Multiple Sclerosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Diabetes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Diabetes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Diabetes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Diabetes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Diabetes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Inflammatory Bowel Disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Inflammatory Bowel Disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Inflammatory Bowel Disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Inflammatory Bowel Disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Inflammatory Bowel Disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Autoimmune Disease Therapeutics Submarket Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 38. Autoimmune Disease Therapeutics Submarket Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Autoimmune Disease Therapeutics Submarket Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Autoimmune Disease Therapeutics Submarket Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Autoimmune Disease Therapeutics Submarket Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Immunosuppressant drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Immunosuppressant drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Immunosuppressant drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Immunosuppressant drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Immunosuppressant drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Nonsteroidal anti-inflammatory drugs (NSAIDs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Nonsteroidal anti-inflammatory drugs (NSAIDs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Nonsteroidal anti-inflammatory drugs (NSAIDs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Nonsteroidal anti-inflammatory drugs (NSAIDs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Nonsteroidal anti-inflammatory drugs (NSAIDs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Biologics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Biologics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Biologics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Biologics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Biologics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Corticosteroids Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Corticosteroids Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Corticosteroids Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Corticosteroids Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Corticosteroids Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Hospitals Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Regional Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 88. Regional Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Regional Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Regional Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Regional Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 92. North America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 93. North America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 94. North America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 95. North America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 96. North America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 97. North America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 98. North America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 99. North America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 100. North America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 101. North America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 102. North America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 103. North America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031(US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 104. North America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 105. North America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 106. North America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 107. North America Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 108. North America Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 109 North America Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 110. North America Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 111. North America Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 112. US Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 113. US Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 114. US Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 115. US Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 116. US Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Canada Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118. Canada Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Canada Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Canada Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario W)
Table 121. Canada Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Europe Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123. Europe Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Europe Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table125. Europe Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Europe Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Europe Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128. Europe Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Europe Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Europe Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Europe Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Europe Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. Europe Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Europe Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Europe Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Europe Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Europe Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. Europe Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Europe Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Europe Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Europe Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. UK Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. UK Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. UK Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145. UK Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 146. UK Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Germany Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. Germany Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Germany Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Germany Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Germany Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152. France Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. France Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. France Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario U)
Table 155. France Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %CAGR %),(COVID - Scenario W)
Table 156. France Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Rest of Europe Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. Rest of Europe Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Rest of Europe Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Rest of Europe Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 161. Rest of Europe Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 177. Asia Pacific Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. Asia Pacific Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. Asia Pacific Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. Asia Pacific Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Asia Pacific Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. China Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. China Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. China Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. China Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. China Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. India Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. India Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. India Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. India Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. India Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. Japan Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. Japan Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. Japan Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. Japan Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Japan Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. RoAPAC Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. RoAPAC Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. RoAPAC Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. RoAPAC Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. RoAPAC Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. Middle East Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. Middle East Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. Middle East Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205 Middle East Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. Middle East Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. Middle East Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. Middle East Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. Middle East Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. Middle East Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. Middle East Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212 Middle East Autoimmune Disease Therapeutics Market Forecast Distribution Channel2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213 Middle East Autoimmune Disease Therapeutics Market Forecast Distribution Channel2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. Middle East Autoimmune Disease Therapeutics Market Forecast Distribution Channel2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. Middle East Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. Middle East Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. Latin America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218. Latin America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219. Latin America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. Latin America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. Latin America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222. Latin America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223. Latin America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224. Latin America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225. Latin America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226. Latin America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227. Latin America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 228. Latin America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229 Latin America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230. Latin America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231. Latin America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232 Leading 10 Autoimmune Disease Therapeutics Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 233. Abbott Laboratories Profile 2021 (CEO, HQ, Founded, Website)
Table 234. Abbott Laboratories Autoimmune Disease Therapeutics Selected Recent Contracts 2021 (Date, Programme Indication, Details)
Table 235. Abbott Laboratories Autoimmune Disease Therapeutics Product Offering (Segment, Product Offerings)
Table 236. Hoffmann-La Roche AG Profile 2021 (CEO, HQ, Founded, Website)
Table 237. Hoffmann-La Roche AG Autoimmune Disease Therapeutics Product Offering (Segment, Product Offerings)
Table 238. Johnson and Johnson Profile 2021 (CEO, HQ, Founded, Website)
Table 239. Johnson and Johnson Autoimmune Disease Therapeutics Selected Recent Contracts 2017-2020 (Date, Programme Indication, Details)
Table 240. Johnson and Johnson Autoimmune Disease Therapeutics Product Offering (Segment, Product Offerings)
Table 241. Bio-Rad Laboratories, Inc. Profile 2021 (CEO, HQ, Founded, Website)
Table 242. Bio-Rad Laboratories, Inc. Selected Recent Contracts 2015-2021 (Date, Programme Indication, Details)
Table 243. Bio-Rad Laboratories, Inc. Autoimmune Disease Therapeutics Product Offering (Segment, Product Offerings)
Table 244. Pfizer, Inc Profile 2021 (CEO, HQ, Founded, Website)
Table 245 Pfizer, Inc Autoimmune Disease Therapeutics Product Offering (Segment, Product Offerings)
Table 246. Bristol-Myers Squibb Profile 2021 (CEO, HQ, Founded, Website)
Table 247. Bristol-Myers Squibb Autoimmune Disease Therapeutics Selected Recent Contracts 2015-2021 (Date, Programme Indication, Details)
Table 248 Bristol-Myers Squibb Autoimmune Disease Therapeutics Product Offering (Segment, Product Offerings)
Table 249. GlaxoSmithKline PLC Profile 2021 (CEO, HQ, Founded, Website)
Table 250. GlaxoSmithKline PLC Autoimmune Disease Therapeutics Product Offering (Segment, Product Offerings)
Table 251. Biogen Inc Profile 2021 (CEO, HQ, Founded, Website)
Table 252. Biogen Inc Autoimmune Disease Therapeutics Product Offering (Segment, Product Offerings)
Table 253. Bayer AG Profile 2021 (CEO, HQ, Founded, Website)
Table 254. Bayer AG Autoimmune Disease Therapeutics Product Offering (Segment, Product Offerings)
Table 255. Merck & Co., Inc Profile 2021 (CEO, Total Company Sales US$m, HQ, Founded, No. of Employees, Ticker, Website)
Table 256. Merck & Co., Inc Total Company Sales 2015-2021 (US$m, AGR %)
Table 257. Merck & Co., Inc Product Offering (Segment, Product Offerings)
Table 258. Other Companies Involved in the Autoimmune Disease Therapeutics Market (Company, Location)
LIST OF FIGURES
Figure 1. Autoimmune Disease Therapeutics Market Indication Overview
Figure 2. Autoimmune Disease Therapeutics Market By Indication Overview
Figure 3. Autoimmune Disease Therapeutics Market By Drug Class Overview
Figure 4. Autoimmune Disease Therapeutics Market Distribution Channel Overview
Figure 5 Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 6. Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 7. Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 8. Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 9. Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 10. Autoimmune Disease Therapeutics Submarket Forecast By Indication 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 11. Autoimmune Disease Therapeutics Submarket Forecast By Indication 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 12. Autoimmune Disease Therapeutics Submarket Forecast By Indication 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 13. Autoimmune Disease Therapeutics Submarket Forecast By Indication 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 14. Autoimmune Disease Therapeutics Submarket Forecast By Indication 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 15. Autoimmune Disease Therapeutics Submarket Forecast By Drug Class 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 16. Autoimmune Disease Therapeutics Submarket Forecast By Drug Class 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 17. Autoimmune Disease Therapeutics Submarket Forecast By Drug Class 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 18. Autoimmune Disease Therapeutics Submarket Forecast By Drug Class 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 19. Autoimmune Disease Therapeutics Submarket Forecast By Drug Class 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 20. Autoimmune Disease Therapeutics Submarket Forecast Distribution Channel 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 21. Autoimmune Disease Therapeutics Submarket Forecast Distribution Channel 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 22. Autoimmune Disease Therapeutics Submarket Forecast Distribution Channel 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 23. Autoimmune Disease Therapeutics Submarket Forecast Distribution Channel 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 24. Autoimmune Disease Therapeutics Submarket Forecast Distribution Channel 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 25. Regional Autoimmune Disease Therapeutics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (Before COVID)
Figure 26. Regional Autoimmune Disease Therapeutics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure 27. Regional Autoimmune Disease Therapeutics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 28. Regional Autoimmune Disease Therapeutics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 29. Regional Autoimmune Disease Therapeutics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 30. North America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %) (Before COVID)
Figure 31. North America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 32. North America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 33. North America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 34. North America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 35. North America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %) (Before COVID)
Figure 36. North America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 37. North America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 38. North America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 39. North America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 40. North America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %) (Before COVID)
Figure 41. North America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 42. North America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 43. North America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 44. North America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 45. North America Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 46. North America Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 47. North America Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 48. North America Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 49. North America Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 50. US Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 51. US Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 52. US Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 53. US Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 54. US Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 55. Canada Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 56. Canada Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 57. Canada Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 58. Canada Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 59. Canada Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 60. Europe Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M)
Figure 61. Europe Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario V)
Figure 62. Europe Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario U)
Figure 63. Europe Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario W)
Figure 64. Europe Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario L)
Figure 65. Europe Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (Before COVID)
Figure 66. Europe Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario V)
Figure 67. Europe Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario U)
Figure 68. Europe Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario W)
Figure 69. Europe Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario L)
Figure 70. Europe Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (Before COVID)
Figure 71. Europe Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario V)
Figure 72. Europe Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario U)
Figure 73. Europe Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario W)
Figure 74. Europe Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario L)
Figure 75. Europe Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 76. Europe Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 77. Europe Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 78. Europe Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 79. Europe Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 80. UK Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 81. UK Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 82. UK Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 83. UK Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 84. UK Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 85. Germany Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 86. Germany Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 87. Germany Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 88. Germany Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 89. Germany Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 90. France Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 91. France Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 92. France Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 93. France Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 94. France Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 95. Rest of Europe Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 96. Rest of Europe Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 97. Rest of Europe Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 98. Rest of Europe Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 99. Rest of Europe Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 100 Asia-Pacific Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (Before COVID)
Figure 101. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario V)
Figure 102. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario U)
Figure 103. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario W)
Figure 104. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario L)
Figure 105. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M)
Figure 106. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario V)
Figure 107. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario U)
Figure 108. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario W)
Figure 109. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario L)
Figure 110. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M)
Figure 111. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario V)
Figure 112. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario U)
Figure 113. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario W)
Figure 114. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario L)
Figure 115. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 116. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 117. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 118. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 119. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 120. China Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 121. China Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 122. China Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 123 China Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 124. China Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 125. India Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 126. India Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 127. India Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 128. India Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 129. India Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 130. Japan Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 131. Japan Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 132. Japan Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 133. Japan Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 134. Japan Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 135. Rest of APAC Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 136. Rest of APAC Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 137 Rest of APAC Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 138. Rest of APAC Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 139. Rest of APAC Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 140. Middle East Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M)
Figure 141. Middle East Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario V)
Figure 142. Middle East Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario U)
Figure 143. Middle East Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario W)
Figure 144. Middle East Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario L)
Figure 145. Middle East Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M)
Figure 146. Middle East Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario V)
Figure 147 Middle East Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario U)
Figure 148. Middle East Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario W)
Figure 149. Middle East Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario L)
Figure 150. Middle East Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M)
Figure 151. Middle East Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario V)
Figure 152. Middle East Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario U)
Figure 153. Middle East Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario W)
Figure 154. Middle East Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario L)
Figure 155. Rest of Middle East Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 156. Rest of Middle East Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 157. Rest of Middle East Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 158. Rest of Middle East Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 159. Rest of Middle East Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 160. Latin America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M)
Figure 161. Latin America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario V)
Figure 162. Latin America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario U)
Figure 163. Latin America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario W)
Figure 164. Latin America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario L)
Figure 165. Latin America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M)
Figure 166. Latin America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario V)
Figure 167. Latin America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario U)
Figure 168. Latin America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario W)
Figure 169. Latin America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario L)
Figure 170. Latin America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M)
Figure 171. Latin America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario V)
Figure 172. Latin America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario U)
Figure 173. Latin America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario W)
Figure 174. Latin America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario L)
Figure 175. Rest of Latin America Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 176. Rest of Latin America Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 177. Rest of Latin America Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 178. Rest of Latin America Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 179. Rest of Latin America Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 180. Porter’s Five Force Analysis
Companies Mentioned
1. Abbott Laboratories
2. Hoffmann-La Roche AG
3. Johnson and Johnson
4. Bio-Rad Laboratories, Inc.
5. Pfizer, Inc
6. Bristol-Myers Squibb
7. GlaxoSmithKline PLC
8. Biogen Inc
9. Bayer AG
10. Merck & Co., Inc.
11. AbbVie, Inc.
12. Sanofi
13. Chugai Pharmaceutical Co. Ltd.
14. Amgen, Inc.
15. Sosei Group
16. Xencor, Inc
17. Novartis AG.
18. Corbus Pharmaceuticals Holdings, Inc.
19. Gilead Sciences, Inc.
20. Takeda Pharmaceutical Company Limited.
21. Celltrion Healthcare Co., Ltd
22. Biogen Idec Inc.,
23. Calliditas Therapeutics AB
24. Eli Lilly and Company,
25. Genentech Inc.,
26. Elan Corporation Plc
27. Eisai, Co., Ltd.
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Autoimmune Disease Therapeutics Market
2.1. Autoimmune Disease Therapeutics Market Definition
2.2. By Indication Submarkets Definitions
2.3. By Drug Class Submarkets Definitions
2.4. By Distribution Channel Submarkets Definitions
3. Autoimmune Disease Therapeutics Market Overview
3.1. Global Autoimmune Disease Therapeutics Market Size and Forecast by Region
3.2. Global Autoimmune Disease Therapeutics Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Surge in adoption of autoimmune disease therapeutics.
3.3.1.2. Rising prevalence of autoimmune disease.
3.3.1.3. Orphan Drug Act boosts market growth.
3.3.1.4. Increasing availability of advanced therapeutics.
3.3.2. Market Restraints/Challenges
3.3.2.1. Higher cost associated with advanced therapeutics for autoimmune disease
3.3.2.2. Lack of investments in the developing economies.
3.3.3. Opportunities
3.3.3.1. Increasing presence of pipeline drug
3.3.3.2. Significant advancement in therapeutics.
3.3.4. Porter’s Five Forces Analysis
3.3.4.1. Competitive Rivalry
3.3.4.2. Supplier Power
3.3.4.3. Buyer Power
3.3.4.4. Threat of Substitution
3.3.4.5. Threat of New Entry
4. Global Autoimmune Disease Therapeutics Market Analysis and Forecast 2021-2031, By Indication (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Rheumatic Disease
4.1.2. It is long-term autoimmune disorder, which primarily affects joints.
4.1.3. Multiple Sclerosis
4.1.4. The multiple sclerosis is potentially disabling disease of the brain and spinal cord.
4.1.5. Diabetes
4.1.6. Type 1 diabetes is autoimmune disease; the children with type 1 diabetes are at risk of other autoimmune disorder.
4.1.7. Inflammatory Bowel Disease
4.1.8. Crohn's disease is type of inflammatory bowel disease, characterized by inflammation of the lining of digestive tract.
4.1.9. Other
5. Global Autoimmune Disease Therapeutics Market Analysis and Forecast, 2021-2031 By Drug Class (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Immunosuppressant drugs
5.1.2. The drug is used to treat certain autoimmune diseases, such as lupus and rheumatoid arthritis.
5.1.3. Nonsteroidal anti-inflammatory drugs (NSAIDs)
5.1.4. The Nonsteroidal anti-inflammatory drugs such as aspirin and ibuprofen, enables to reduce pain and inflammation.
5.1.5. Biologics
5.1.6. Biologics categorized as Tumor necrosis factor (TNF) inhibitors; Interleukin (IL) inhibitors; B-cells inhibitors; and T-cells inhibitors to treat biologic autoimmune disease.
5.1.7. Corticosteroids
5.1.8. Corticosteroids are a class of drug, enables to reduce inflammation in the body.
5.1.9. Others
6. Global Autoimmune Disease Therapeutics Market Analysis and Forecast, 2021-2031 Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Hospital Pharmacy
6.1.2. Extensively increasing demand in hospitals.
6.1.3. Online Pharmacies
6.1.4. Increasing demand for online pharmacies due to pandemic impact.
6.1.5. Other
7. North America Autoimmune Disease Therapeutics Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Autoimmune Disease Therapeutics Market Size and Forecast By Indication
7.3. North America Autoimmune Disease Therapeutics Market Size and Forecast By Drug Class
7.4. North America Autoimmune Disease Therapeutics Market Size and Forecast By Distribution Channel
7.5. U.S. Autoimmune Disease Therapeutics Market
7.5.1. Increasing FDA approved orphan drug designation to treat autoimmune diseases.
7.6. Canada Autoimmune Disease Therapeutics Market
7.6.1. Approval of biologics therapy in the region.
8. Europe Autoimmune Disease Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Autoimmune Disease Therapeutics Market Size and Forecast By Indication
8.3. Europe Autoimmune Disease Therapeutics Market Size and Forecast By Drug Class
8.4. Europe Autoimmune Disease Therapeutics Market Size and Forecast By Distribution Channel
8.5. UK Autoimmune Disease Therapeutics Market
8.5.1. Increasing incentives to encourage the development of medicinal products for the treatment of rare diseases.
8.6. Germany Autoimmune Disease Therapeutics Market
8.6.1. Approval of MabThera to treat four autoimmune diseases in the region.
8.7. France Autoimmune Disease Therapeutics Market
8.7.1. Increasing healthcare awareness and emerging need for autoimmune disease therapeutics in the region.
8.8. Rest of Europe Autoimmune Disease Therapeutics Market
9. Asia Pacific Autoimmune Disease Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Autoimmune Disease Therapeutics Market Size and Forecast By Indication
9.3. Asia Pacific Autoimmune Disease Therapeutics Market Size and Forecast By Technology
9.4. Asia Pacific Autoimmune Disease Therapeutics Market Size and Forecast By Distribution Channel
9.5. China Autoimmune Disease Therapeutics Market
9.5.1. Rising prevalence of systemic sclerosis (SSc) in the region.
9.6. India Autoimmune Disease Therapeutics Market
9.6.1. Increasing prevalence of Grave's and Hashimoto's, inflammatory bowel diseases in the region.
9.7. Japan Autoimmune Disease Therapeutics Market
9.7.1. Increasing incidences of autoimmune disorder.
9.8. Rest of Asia Pacific Autoimmune Disease Therapeutics Market
10. Latin America Autoimmune Disease Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Autoimmune Disease Therapeutics Market Size and Forecast By Indication
10.3. Latin America Autoimmune Disease Therapeutics Market Size and Forecast By Drug Class
10.4. Latin America Autoimmune Disease Therapeutics Market Size and Forecast By Distribution Channel
10.4.1. Brazil Autoimmune Disease Therapeutics Market
10.4.1.1. Increasing risk of autoimmune disorder & lack of specific polices.
10.4.2. Mexico Autoimmune Disease Therapeutics Market
10.4.2.1. Prevalence of Arthritis in the region.
10.4.3. Rest of Latin America Autoimmune Disease Therapeutics Market
11. MEA Autoimmune Disease Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Autoimmune Disease Therapeutics Market Size and Forecast By Indication
11.3. MEA Autoimmune Disease Therapeutics Market Size and Forecast By Drug Class
11.4. MEA Autoimmune Disease Therapeutics Market Size and Forecast By Distribution Channel
11.5. South Africa Autoimmune Disease Therapeutics Market
11.5.1.1. Lack of awareness among population.
11.6. Rest of MEA Autoimmune Disease Therapeutics Market
12. Companies in the Autoimmune Disease Therapeutics Market
12.1. 1. Abbott Laboratories
12.1.1. Company Snapshot
12.1.2. Company Overview
12.1.3. Financial Performance (2015-2020)
12.1.3.1. Net Revenue
12.1.4. Product Offerings
12.1.5. Recent Initiatives (2017-2020)
12.2. Hoffmann-La Roche AG
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2020)
12.2.3.1. Net Revenue
12.2.3.2. Geographical Revenue, 2020
12.2.4. Product Offerings
12.2.5. Recent Initiatives (2017-2020)
12.3. Johnson and Johnson
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2020)
12.3.3.1. Net Revenue
12.3.3.2. Gross Profit
12.3.3.3. Geographical Revenue, 2020
12.3.4. Product Offerings
12.3.5. Recent Initiatives (2017-2020)
12.4. Bio-Rad Laboratories, Inc.
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2020)
12.4.3.1. Net Revenue
12.4.3.2. Gross Profit
12.4.3.3. Geographical Revenue, 2020
12.4.4. Product Offerings
12.4.5. Recent Initiatives (2017-2020)
12.5. Pfizer, Inc
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2020)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2020
12.5.4. Product Offerings
12.5.5. Recent Initiatives (2017-2020)
12.6. Bristol-Myers Squibb
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2020)
12.6.3.1. Net Revenue
12.6.3.2. Geographical Revenue, 2020
12.6.4. Product Offerings
12.6.5. Recent Initiatives (2017-2020)
12.7. GlaxoSmithKline PLC
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2020)
12.7.3.1. Net Revenue
12.7.3.2. Geographical Revenue, 2020
12.7.4. Product Offerings
12.7.5. Recent Initiatives (2017-2020)
12.8. Biogen Inc
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2020)
12.8.3.1. Net Revenue
12.8.3.2. Geographical Revenue, 2020
12.8.4. Product Offerings
12.8.5. Recent Initiatives (2017-2020)
12.9. Bayer AG
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2020)
12.9.3.1. Net Revenue
12.9.3.2. Geographical Revenue, 2020
12.9.4. Product Offerings
12.9.5. Recent Initiatives (2017-2020)
12.10. Merck & Co., Inc.
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2020)
12.10.3.1. Net Revenue
12.10.3.2. Geographical Revenue, 2020
12.10.4. Product Offerings
12.10.5. Recent Initiatives (2017-2020)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Autoimmune Disease Therapeutics Market Drivers & Restraints 2021
Table 7. Autoimmune Disease Therapeutics Submarket Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Autoimmune Disease Therapeutics Submarket Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Autoimmune Disease Therapeutics Submarket Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Autoimmune Disease Therapeutics Submarket Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Autoimmune Disease Therapeutics Submarket Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Rheumatic Disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Rheumatic Disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Rheumatic Disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Rheumatic Disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Rheumatic Disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Multiple Sclerosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Multiple Sclerosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Multiple Sclerosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Multiple Sclerosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Multiple Sclerosis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Diabetes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Diabetes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Diabetes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Diabetes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Diabetes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Inflammatory Bowel Disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Inflammatory Bowel Disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Inflammatory Bowel Disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Inflammatory Bowel Disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Inflammatory Bowel Disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Autoimmune Disease Therapeutics Submarket Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 38. Autoimmune Disease Therapeutics Submarket Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Autoimmune Disease Therapeutics Submarket Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Autoimmune Disease Therapeutics Submarket Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Autoimmune Disease Therapeutics Submarket Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Immunosuppressant drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Immunosuppressant drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Immunosuppressant drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Immunosuppressant drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Immunosuppressant drugs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Nonsteroidal anti-inflammatory drugs (NSAIDs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Nonsteroidal anti-inflammatory drugs (NSAIDs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Nonsteroidal anti-inflammatory drugs (NSAIDs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Nonsteroidal anti-inflammatory drugs (NSAIDs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Nonsteroidal anti-inflammatory drugs (NSAIDs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Biologics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Biologics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Biologics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Biologics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Biologics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Corticosteroids Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Corticosteroids Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Corticosteroids Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Corticosteroids Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Corticosteroids Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Hospitals Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Regional Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 88. Regional Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Regional Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Regional Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Regional Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 92. North America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 93. North America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 94. North America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 95. North America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 96. North America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 97. North America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 98. North America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 99. North America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 100. North America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 101. North America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 102. North America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 103. North America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031(US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 104. North America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 105. North America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 106. North America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 107. North America Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 108. North America Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 109 North America Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 110. North America Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 111. North America Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 112. US Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 113. US Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 114. US Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 115. US Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 116. US Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Canada Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118. Canada Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Canada Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Canada Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario W)
Table 121. Canada Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Europe Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123. Europe Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Europe Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table125. Europe Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Europe Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Europe Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128. Europe Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Europe Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Europe Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Europe Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Europe Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. Europe Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Europe Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Europe Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Europe Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Europe Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. Europe Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Europe Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Europe Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Europe Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. UK Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. UK Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. UK Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145. UK Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 146. UK Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Germany Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. Germany Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Germany Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Germany Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Germany Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152. France Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. France Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. France Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario U)
Table 155. France Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %CAGR %),(COVID - Scenario W)
Table 156. France Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Rest of Europe Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. Rest of Europe Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Rest of Europe Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Rest of Europe Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 161. Rest of Europe Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Asia Pacific Autoimmune Disease Therapeutics Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 177. Asia Pacific Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. Asia Pacific Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. Asia Pacific Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. Asia Pacific Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Asia Pacific Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. China Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. China Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. China Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. China Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. China Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. India Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. India Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. India Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. India Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. India Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. Japan Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. Japan Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. Japan Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. Japan Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Japan Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. RoAPAC Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. RoAPAC Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. RoAPAC Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. RoAPAC Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. RoAPAC Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. Middle East Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. Middle East Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. Middle East Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205 Middle East Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. Middle East Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. Middle East Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. Middle East Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. Middle East Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. Middle East Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. Middle East Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212 Middle East Autoimmune Disease Therapeutics Market Forecast Distribution Channel2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213 Middle East Autoimmune Disease Therapeutics Market Forecast Distribution Channel2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. Middle East Autoimmune Disease Therapeutics Market Forecast Distribution Channel2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. Middle East Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. Middle East Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. Latin America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218. Latin America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219. Latin America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. Latin America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. Latin America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222. Latin America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223. Latin America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224. Latin America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225. Latin America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226. Latin America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227. Latin America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 228. Latin America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229 Latin America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230. Latin America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231. Latin America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232 Leading 10 Autoimmune Disease Therapeutics Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 233. Abbott Laboratories Profile 2021 (CEO, HQ, Founded, Website)
Table 234. Abbott Laboratories Autoimmune Disease Therapeutics Selected Recent Contracts 2021 (Date, Programme Indication, Details)
Table 235. Abbott Laboratories Autoimmune Disease Therapeutics Product Offering (Segment, Product Offerings)
Table 236. Hoffmann-La Roche AG Profile 2021 (CEO, HQ, Founded, Website)
Table 237. Hoffmann-La Roche AG Autoimmune Disease Therapeutics Product Offering (Segment, Product Offerings)
Table 238. Johnson and Johnson Profile 2021 (CEO, HQ, Founded, Website)
Table 239. Johnson and Johnson Autoimmune Disease Therapeutics Selected Recent Contracts 2017-2020 (Date, Programme Indication, Details)
Table 240. Johnson and Johnson Autoimmune Disease Therapeutics Product Offering (Segment, Product Offerings)
Table 241. Bio-Rad Laboratories, Inc. Profile 2021 (CEO, HQ, Founded, Website)
Table 242. Bio-Rad Laboratories, Inc. Selected Recent Contracts 2015-2021 (Date, Programme Indication, Details)
Table 243. Bio-Rad Laboratories, Inc. Autoimmune Disease Therapeutics Product Offering (Segment, Product Offerings)
Table 244. Pfizer, Inc Profile 2021 (CEO, HQ, Founded, Website)
Table 245 Pfizer, Inc Autoimmune Disease Therapeutics Product Offering (Segment, Product Offerings)
Table 246. Bristol-Myers Squibb Profile 2021 (CEO, HQ, Founded, Website)
Table 247. Bristol-Myers Squibb Autoimmune Disease Therapeutics Selected Recent Contracts 2015-2021 (Date, Programme Indication, Details)
Table 248 Bristol-Myers Squibb Autoimmune Disease Therapeutics Product Offering (Segment, Product Offerings)
Table 249. GlaxoSmithKline PLC Profile 2021 (CEO, HQ, Founded, Website)
Table 250. GlaxoSmithKline PLC Autoimmune Disease Therapeutics Product Offering (Segment, Product Offerings)
Table 251. Biogen Inc Profile 2021 (CEO, HQ, Founded, Website)
Table 252. Biogen Inc Autoimmune Disease Therapeutics Product Offering (Segment, Product Offerings)
Table 253. Bayer AG Profile 2021 (CEO, HQ, Founded, Website)
Table 254. Bayer AG Autoimmune Disease Therapeutics Product Offering (Segment, Product Offerings)
Table 255. Merck & Co., Inc Profile 2021 (CEO, Total Company Sales US$m, HQ, Founded, No. of Employees, Ticker, Website)
Table 256. Merck & Co., Inc Total Company Sales 2015-2021 (US$m, AGR %)
Table 257. Merck & Co., Inc Product Offering (Segment, Product Offerings)
Table 258. Other Companies Involved in the Autoimmune Disease Therapeutics Market (Company, Location)
LIST OF FIGURES
Figure 1. Autoimmune Disease Therapeutics Market Indication Overview
Figure 2. Autoimmune Disease Therapeutics Market By Indication Overview
Figure 3. Autoimmune Disease Therapeutics Market By Drug Class Overview
Figure 4. Autoimmune Disease Therapeutics Market Distribution Channel Overview
Figure 5 Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 6. Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 7. Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 8. Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 9. Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 10. Autoimmune Disease Therapeutics Submarket Forecast By Indication 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 11. Autoimmune Disease Therapeutics Submarket Forecast By Indication 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 12. Autoimmune Disease Therapeutics Submarket Forecast By Indication 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 13. Autoimmune Disease Therapeutics Submarket Forecast By Indication 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 14. Autoimmune Disease Therapeutics Submarket Forecast By Indication 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 15. Autoimmune Disease Therapeutics Submarket Forecast By Drug Class 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 16. Autoimmune Disease Therapeutics Submarket Forecast By Drug Class 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 17. Autoimmune Disease Therapeutics Submarket Forecast By Drug Class 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 18. Autoimmune Disease Therapeutics Submarket Forecast By Drug Class 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 19. Autoimmune Disease Therapeutics Submarket Forecast By Drug Class 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 20. Autoimmune Disease Therapeutics Submarket Forecast Distribution Channel 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 21. Autoimmune Disease Therapeutics Submarket Forecast Distribution Channel 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 22. Autoimmune Disease Therapeutics Submarket Forecast Distribution Channel 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 23. Autoimmune Disease Therapeutics Submarket Forecast Distribution Channel 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 24. Autoimmune Disease Therapeutics Submarket Forecast Distribution Channel 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 25. Regional Autoimmune Disease Therapeutics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (Before COVID)
Figure 26. Regional Autoimmune Disease Therapeutics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure 27. Regional Autoimmune Disease Therapeutics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 28. Regional Autoimmune Disease Therapeutics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 29. Regional Autoimmune Disease Therapeutics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 30. North America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %) (Before COVID)
Figure 31. North America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 32. North America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 33. North America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 34. North America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 35. North America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %) (Before COVID)
Figure 36. North America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 37. North America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 38. North America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 39. North America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 40. North America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %) (Before COVID)
Figure 41. North America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 42. North America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 43. North America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 44. North America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 45. North America Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 46. North America Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 47. North America Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 48. North America Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 49. North America Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 50. US Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 51. US Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 52. US Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 53. US Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 54. US Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 55. Canada Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 56. Canada Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 57. Canada Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 58. Canada Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 59. Canada Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 60. Europe Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M)
Figure 61. Europe Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario V)
Figure 62. Europe Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario U)
Figure 63. Europe Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario W)
Figure 64. Europe Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario L)
Figure 65. Europe Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (Before COVID)
Figure 66. Europe Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario V)
Figure 67. Europe Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario U)
Figure 68. Europe Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario W)
Figure 69. Europe Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario L)
Figure 70. Europe Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (Before COVID)
Figure 71. Europe Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario V)
Figure 72. Europe Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario U)
Figure 73. Europe Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario W)
Figure 74. Europe Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario L)
Figure 75. Europe Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 76. Europe Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 77. Europe Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 78. Europe Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 79. Europe Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 80. UK Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 81. UK Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 82. UK Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 83. UK Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 84. UK Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 85. Germany Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 86. Germany Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 87. Germany Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 88. Germany Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 89. Germany Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 90. France Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 91. France Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 92. France Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 93. France Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 94. France Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 95. Rest of Europe Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 96. Rest of Europe Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 97. Rest of Europe Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 98. Rest of Europe Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 99. Rest of Europe Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 100 Asia-Pacific Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (Before COVID)
Figure 101. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario V)
Figure 102. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario U)
Figure 103. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario W)
Figure 104. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario L)
Figure 105. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M)
Figure 106. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario V)
Figure 107. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario U)
Figure 108. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario W)
Figure 109. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario L)
Figure 110. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M)
Figure 111. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario V)
Figure 112. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario U)
Figure 113. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario W)
Figure 114. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario L)
Figure 115. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 116. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 117. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 118. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 119. Asia-Pacific Autoimmune Disease Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 120. China Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 121. China Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 122. China Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 123 China Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 124. China Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 125. India Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 126. India Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 127. India Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 128. India Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 129. India Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 130. Japan Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 131. Japan Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 132. Japan Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 133. Japan Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 134. Japan Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 135. Rest of APAC Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 136. Rest of APAC Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 137 Rest of APAC Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 138. Rest of APAC Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 139. Rest of APAC Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 140. Middle East Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M)
Figure 141. Middle East Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario V)
Figure 142. Middle East Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario U)
Figure 143. Middle East Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario W)
Figure 144. Middle East Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario L)
Figure 145. Middle East Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M)
Figure 146. Middle East Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario V)
Figure 147 Middle East Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario U)
Figure 148. Middle East Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario W)
Figure 149. Middle East Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario L)
Figure 150. Middle East Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M)
Figure 151. Middle East Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario V)
Figure 152. Middle East Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario U)
Figure 153. Middle East Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario W)
Figure 154. Middle East Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario L)
Figure 155. Rest of Middle East Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 156. Rest of Middle East Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 157. Rest of Middle East Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 158. Rest of Middle East Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 159. Rest of Middle East Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 160. Latin America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M)
Figure 161. Latin America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario V)
Figure 162. Latin America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario U)
Figure 163. Latin America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario W)
Figure 164. Latin America Autoimmune Disease Therapeutics Market Forecast By Indication 2021-2031 (US$M) (COVID - Scenario L)
Figure 165. Latin America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M)
Figure 166. Latin America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario V)
Figure 167. Latin America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario U)
Figure 168. Latin America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario W)
Figure 169. Latin America Autoimmune Disease Therapeutics Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario L)
Figure 170. Latin America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M)
Figure 171. Latin America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario V)
Figure 172. Latin America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario U)
Figure 173. Latin America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario W)
Figure 174. Latin America Autoimmune Disease Therapeutics Market Forecast Distribution Channel 2021-2031 (US$M) (COVID - Scenario L)
Figure 175. Rest of Latin America Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 176. Rest of Latin America Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 177. Rest of Latin America Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 178. Rest of Latin America Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 179. Rest of Latin America Autoimmune Disease Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 180. Porter’s Five Force Analysis
Companies Mentioned
1. Abbott Laboratories
2. Hoffmann-La Roche AG
3. Johnson and Johnson
4. Bio-Rad Laboratories, Inc.
5. Pfizer, Inc
6. Bristol-Myers Squibb
7. GlaxoSmithKline PLC
8. Biogen Inc
9. Bayer AG
10. Merck & Co., Inc.
11. AbbVie, Inc.
12. Sanofi
13. Chugai Pharmaceutical Co. Ltd.
14. Amgen, Inc.
15. Sosei Group
16. Xencor, Inc
17. Novartis AG.
18. Corbus Pharmaceuticals Holdings, Inc.
19. Gilead Sciences, Inc.
20. Takeda Pharmaceutical Company Limited.
21. Celltrion Healthcare Co., Ltd
22. Biogen Idec Inc.,
23. Calliditas Therapeutics AB
24. Eli Lilly and Company,
25. Genentech Inc.,
26. Elan Corporation Plc
27. Eisai, Co., Ltd.
Companies Profiled in the Report
1. ABBOTT Laboratories
2. Hoffmann-La Roche AG
3. Johnson and Johnson
4. Bio-Rad Laboratories, Inc.
5. Pfizer, Inc
6. Bristol-Myers Squibb
7. GlaxoSmithKline PLC
8. Biogen Inc
9. Bayer AG
10. Merck & Co., Inc.
11. AbbVie, Inc.
12. Sanofi
13. Chugai Pharmaceutical Co. Ltd.
14. Amgen, Inc.
List of Companies Mentioned in the Report:
1. Abbott Laboratories
2. Hoffmann-La Roche AG
3. Johnson and Johnson
4. Bio-Rad Laboratories, Inc.
5. Pfizer, Inc
6. Bristol-Myers Squibb
7. GlaxoSmithKline PLC
8. Biogen Inc
9. Bayer AG
10. Merck & Co., Inc.
11. AbbVie, Inc.
12. Sanofi
13. Chugai Pharmaceutical Co. Ltd.
14. Amgen, Inc.
15. Sosei Group
16. Xencor, Inc
17. Novartis AG.
18. Corbus Pharmaceuticals Holdings, Inc.
19. Gilead Sciences, Inc.
20. Takeda Pharmaceutical Company Limited.
21. Celltrion Healthcare Co. Ltd
22. Biogen Idec Inc.,
23. Calliditas Therapeutics AB
24. Eli Lilly and Company,
25. Genentech Inc.,
26. Elan Corporation Plc
27. Eisai, Co., Ltd.
List of Organizations Mentioned in the Report
1. World Health Organization
2. American Academy of Dermatology Association.
3. National Psoriasis Foundation
4. Mount Sinai Hospital
5. American Academy of Allergy, Asthma & Immunology
6. Bingham Memorial Hospital.
7. American College of Cardiology
8. National Center for Biotechnology Information
9. National Institute for Health and Care Excellence
10. European Association of Hospital Pharmacy
11. The International Society on Thrombosis and Haemostasis
12. American Heart Association
13. International Society of Blood Transfusion.
14. Stanford Healthcare
15. Epidemic Analysis Dashboard
16. American University Radio
17. Massachusetts Medical Society.
18. The European Medicines Agency (EMA)
19. US Food & Drug Administration
20. US National Library of Medicine
21. National Institutes of Health
22. The Biomedical Advanced Research and Development Authority (BARDA)
23. National Organisation for Rare Diseases
24. National Association for Biomedical Research
25. Center for Disease Control and Prevention CDC
26. Journal of the American college of Cardiology
27. Center for Diseases Dynamics, Economics & Policy (CDDEP)
28. The Global Health Security Agenda (GHSA)
29. American Society of Microbiology
30. National Institute on Drug Abuse
31. The United Nations Office on Drugs and Crime (UNODC)
1. ABBOTT Laboratories
2. Hoffmann-La Roche AG
3. Johnson and Johnson
4. Bio-Rad Laboratories, Inc.
5. Pfizer, Inc
6. Bristol-Myers Squibb
7. GlaxoSmithKline PLC
8. Biogen Inc
9. Bayer AG
10. Merck & Co., Inc.
11. AbbVie, Inc.
12. Sanofi
13. Chugai Pharmaceutical Co. Ltd.
14. Amgen, Inc.
List of Companies Mentioned in the Report:
1. Abbott Laboratories
2. Hoffmann-La Roche AG
3. Johnson and Johnson
4. Bio-Rad Laboratories, Inc.
5. Pfizer, Inc
6. Bristol-Myers Squibb
7. GlaxoSmithKline PLC
8. Biogen Inc
9. Bayer AG
10. Merck & Co., Inc.
11. AbbVie, Inc.
12. Sanofi
13. Chugai Pharmaceutical Co. Ltd.
14. Amgen, Inc.
15. Sosei Group
16. Xencor, Inc
17. Novartis AG.
18. Corbus Pharmaceuticals Holdings, Inc.
19. Gilead Sciences, Inc.
20. Takeda Pharmaceutical Company Limited.
21. Celltrion Healthcare Co. Ltd
22. Biogen Idec Inc.,
23. Calliditas Therapeutics AB
24. Eli Lilly and Company,
25. Genentech Inc.,
26. Elan Corporation Plc
27. Eisai, Co., Ltd.
List of Organizations Mentioned in the Report
1. World Health Organization
2. American Academy of Dermatology Association.
3. National Psoriasis Foundation
4. Mount Sinai Hospital
5. American Academy of Allergy, Asthma & Immunology
6. Bingham Memorial Hospital.
7. American College of Cardiology
8. National Center for Biotechnology Information
9. National Institute for Health and Care Excellence
10. European Association of Hospital Pharmacy
11. The International Society on Thrombosis and Haemostasis
12. American Heart Association
13. International Society of Blood Transfusion.
14. Stanford Healthcare
15. Epidemic Analysis Dashboard
16. American University Radio
17. Massachusetts Medical Society.
18. The European Medicines Agency (EMA)
19. US Food & Drug Administration
20. US National Library of Medicine
21. National Institutes of Health
22. The Biomedical Advanced Research and Development Authority (BARDA)
23. National Organisation for Rare Diseases
24. National Association for Biomedical Research
25. Center for Disease Control and Prevention CDC
26. Journal of the American college of Cardiology
27. Center for Diseases Dynamics, Economics & Policy (CDDEP)
28. The Global Health Security Agenda (GHSA)
29. American Society of Microbiology
30. National Institute on Drug Abuse
31. The United Nations Office on Drugs and Crime (UNODC)
Download sample pages
Complete the form below to download your free sample pages for Autoimmune Disease Therapeutics Market Report to 2031Related reports
Bowel Management Systems Market Report 2021-2031
Growing female population with faecal incontinence to fuel bowel management systems market growth through 2031....Full DetailsPublished: 02 August 2021Short Bowel Syndrome Market Report 2021-2031
Where the Short Bowel Syndrome is market heading? If you are involved in this sector you must read this newly...Full DetailsPublished: 01 January 1970The Global Anti-Inflammatory Therapeutics Market Forecast 2017-2027
Our 162-page report provides 108 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry...Full DetailsPublished: 12 June 2017Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031
Rising prevalence of inflammatory bowel disease including Crohn's disease and ulcerative colitis; raising awareness for IBD in developing countries; escalating...Full DetailsPublished: 06 April 2021Bowel Management Systems Market Forecast 2020-2030
The Bowel Management Systems market is projected at USD 2.3 billion in 2020.
...Full DetailsPublished: 01 January 1970
Download sample pages
Complete the form below to download your free sample pages for Autoimmune Disease Therapeutics Market Report to 2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033
The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033
31 May 2023
Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
26 May 2023
Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033
The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033
24 May 2023
Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033
The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033
23 May 2023
